Amedeo Smart

Free Medical Literature Service

 

Amedeo

Parkinson's Disease
  Free Subscription

Articles published in
Neurology
    April 2026
  1. DIAZ-GALVAN P, Franco-Rosado P, Silva-Rodriguez J, Castro-Labrador S, et al
    Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease.
    Neurology. 2026;106:e214947.
    >> Share

  2. NIEMI KJ, Jaakkola E, Myller EM, Eklund MRE, et al
    Striatal Dopamine Transporter and Rest Tremor in Parkinson Disease: A Clinical Validation.
    Neurology. 2026;106:e214811.
    >> Share

  3. SUPER M, Paul RA, Irwin DJ, Aamodt WW, et al
    Teaching Video NeuroImage: C9orf72-Related Parkinsonism.
    Neurology. 2026;106:e214828.
    >> Share

    March 2026
  4. BENARROCH E
    How Are Synaptic Vesicle Exocytosis and Endocytosis Affected in Parkinson Disease?
    Neurology. 2026;106:e214770.
    >> Share

  5. AHN SH, Kim DH, Park J, Yoon J, et al
    Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality: A Competing Risk Analysis Approach.
    Neurology. 2026;106:e214722.
    >> Share

  6. URSO D, Logroscino G
    Dynamic Smoking Patterns and Risk of Parkinson Disease.
    Neurology. 2026;106:e214651.
    >> Share

    February 2026
  7. DIAZ-GALVAN P, Franco-Rosado P, Silva-Rodriguez J, Castro-Labrador S, et al
    Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease.
    Neurology. 2026;106:e214455.
    >> Share

  8. SUN Y, Na HK, Jeon S, Ye BS, et al
    Cerebral Perfusion and Motor Deficits in Drug-Induced Parkinsonism: A Dual-Phase (18)F-FP-CIT PET Study.
    Neurology. 2026;106:e214573.
    >> Share

  9. GERMAN A, Grotemeyer A, Rothhammer V, Doerfler A, et al
    Pearls & Oy-sters: Reversible Leukoencephalopathy and Parkinsonism Due to CNS Involvement in Cryoglobulinemia.
    Neurology. 2026;106:e214622.
    >> Share

  10. THATIKALA A, Boddu AV, Nayar D, Virmani T, et al
    Pearls & Oy-sters: Hereditary Spastic Paraplegia Type 15 Presenting as Juvenile Onset Levodopa-Responsive Parkinsonism.
    Neurology. 2026;106:e214514.
    >> Share

  11. COUGHLIN DG, Adler CH, Barbosa W, Feuerstein J, et al
    CSF alpha-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps.
    Neurology. 2026;106:e214648.
    >> Share

    January 2026
  12. TSUKITA K, Kikuya A, Yoshimura K, Nakanishi E, et al
    Temporal Dynamics and Cross-Sectional and Longitudinal Factors Associated With Motor Reserve and Outcome in Patients With Parkinson Disease.
    Neurology. 2026;106:e214475.
    >> Share

  13. LI CH, Fan SP, Chen PS, Chang YY, et al
    Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.
    Neurology. 2026;106:e214406.
    >> Share

  14. CONTI M, Mascioli D, Simonetta C, Ferrari V, et al
    Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE epsilon4 Carriers.
    Neurology. 2026;106:e214449.
    >> Share

    November 2025
  15. ORSO B, Mattioli P, Fama F, Massa F, et al
    Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the alpha-Synucleinopathy Spectrum.
    Neurology. 2025;105:e214253.
    >> Share

  16. BORGES PGLB, Qureshi Q, Hammer LH, Cajigas I, et al
    Effect of Motor Imagery on Tremor in a Patient With Parkinson Disease Undergoing Intraoperative Testing.
    Neurology. 2025;105:e214246.
    >> Share

  17. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    >> Share

  18. AVENALI M, Artusi CA, Cilia R, Giannini G, et al
    Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant.
    Neurology. 2025;105:e214036.
    >> Share

    October 2025
  19. PERSICO M, Esper CD
    Can Intrinsic Capacity Help Identify Those at Risk of Parkinson Disease?
    Neurology. 2025;105:e214242.
    >> Share

  20. HU W, Tian G, Wang JN, Ma YB, et al
    Intrinsic Capacity Defined Using 4 Domains, Genetic Risk, and Incident Parkinson Disease: A Prospective Cohort Study.
    Neurology. 2025;105:e214144.
    >> Share

  21. KRZYZANOWSKI B, Beyene KM, Turner JR, Racette BA, et al
    Ambient Trichloroethylene Exposure and Parkinson Disease Risk in Medicare Beneficiaries.
    Neurology. 2025;105:e214174.
    >> Share

  22. DORSEY ER, Tanner CM
    Trichloroethylene and Parkinson Disease.
    Neurology. 2025;105:e214245.
    >> Share

  23. DELVA A, Fereshtehnejad SM, Vo A, Yao CW, et al
    Evolution of Motor and Nonmotor Characteristics in an Idiopathic/Isolated REM Sleep Behavior Disorder Cohort.
    Neurology. 2025;105:e214108.
    >> Share

  24. AYRAL V, Pastor-Bernier A, Daneault V, Tremblay C, et al
    Association of DTI-ALPS Glymphatic Index With Differential Phenoconversion in Isolated REM Sleep Behavior Disorder: A Multi-Cohort MRI Study.
    Neurology. 2025;105:e214042.
    >> Share

    September 2025
  25. ZHANG X, Wang J, Dove A, Yu T, et al
    Metabolic Syndrome and Incidence of Parkinson Disease: A Community-Based Longitudinal Study and Meta-Analysis.
    Neurology. 2025;105:e214033.
    >> Share

  26. XUAN Z, Pan Z, Ma C, Lin X, et al
    Reader Response: Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2025;105:e210094.
    >> Share

  27. CHAHINE L, Rosso AL, Troidl I, Ganguli M, et al
    Features of Prodromal Parkinson Disease and Dopaminergic Neurotransmission in Community-Dwelling Older Adults.
    Neurology. 2025;105:e214037.
    >> Share

  28. SCHULZ RS, Rist PM, Kurth T
    Author Response: Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2025;105:e210158.
    >> Share

  29. GANESH A, Galetta SL
    Editors' Note: Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2025;105:e214084.
    >> Share

  30. AITA SL, Roth RM
    Much Ado About Nothing? Midlife Vascular Risk Factors and Incident Parkinson Disease.
    Neurology. 2025;105:e214127.
    >> Share

  31. JOHRI M, Morrill V, Okine DN, Huang X, et al
    Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia: The ARIC Study.
    Neurology. 2025;105:e213931.
    >> Share

  32. GONZALEZ-ESCAMILLA G, Groppa S
    MRI-Based Evidence of Regular Physical Activity's Impact on Brain Networks for Modifying Disease Courses in Parkinson Disease.
    Neurology. 2025;105:e214059.
    >> Share

  33. DIAZ-GALVAN P, Franco-Rosado P, Silva-Rodriguez J, Castro-Labrador S, et al
    Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease.
    Neurology. 2025;105:e213932.
    >> Share

    August 2025
  34. TUOMINEN JA, Riise T, Romanowska J, Flores-Torres MH, et al
    Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation.
    Neurology. 2025;105:e213783.
    >> Share

  35. COLOSIMO C, Marsili L
    It Is Time for Drug Repurposing in Parkinson Disease.
    Neurology. 2025;105:e213972.
    >> Share

    June 2025
  36. WANG P, Chen X, Na M, Flores-Torres MH, et al
    Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease.
    Neurology. 2025;104:e213562.
    >> Share

  37. MARAKI MI, Scarmeas N
    Fast Food, Slow Damage: The Role of Ultraprocessed Foods in Parkinson Disease.
    Neurology. 2025;104:e213684.
    >> Share

  38. YOUNG CB, Cholerton B, Smith AM, Shahid-Besanti M, et al
    The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
    Neurology. 2025;104:e213648.
    >> Share

    May 2025
  39. CHEN CC, Chiu JY, Tan AH, Toh TS, et al
    Investigating Plasma Metabolomics and Gut Microbiota Changes Associated With Parkinson Disease: A Focus on Caffeine Metabolism.
    Neurology. 2025;104:e213592.
    >> Share

  40. BENARROCH E
    What Are Current Concepts on the Functional Organization of the Globus Pallidus Externus and Its Potential Role in Parkinson Disease?
    Neurology. 2025;104:e213623.
    >> Share

  41. POSTUMA RB
    Having Second Thoughts About Parkinson Diagnosis.
    Neurology. 2025;104:e213594.
    >> Share

  42. RATY V, Kuusimaki T, Majuri J, Vahlberg T, et al
    Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years.
    Neurology. 2025;104:e213499.
    >> Share

  43. GANGULY J, Banerjee S, Basu P, Mukherjee S, et al
    Teaching Video NeuroImage: String Hallucinations in Parkinson Disease.
    Neurology. 2025;104:e213611.
    >> Share

    April 2025
  44. SANCHEZ E, Coughlan GT, Wilkinson T, Ramirez J, et al
    Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.
    Neurology. 2025;104:e213438.
    >> Share

    March 2025
  45. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2025;104:e213392.
    >> Share

  46. COUGHLIN DG, Shifflett B, Farris CM, Ma Y, et al
    alpha-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
    Neurology. 2025;104:e210279.
    >> Share

  47. PALERMO G, Francesconi A, Bellini G, Morganti R, et al
    Involvement of the Nigrostriatal Pathway in Patients With Idiopathic Normal Pressure Hydrocephalus and Parkinsonism.
    Neurology. 2025;104:e213352.
    >> Share

  48. LE HERON C, Horne KL, Macaskill MR, Livingston L, et al
    Author Response: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e209958.
    >> Share

  49. ZHANG X, Zhang Y, Ding C, Yang J, et al
    Reader Response: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e209812.
    >> Share

  50. GANESH A, Galetta SL
    Editors' Note: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e213339.
    >> Share

    February 2025
  51. YI MY, Cheng S, Chandra AA, Farkas N, et al
    Teaching Video NeuroImage: Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism.
    Neurology. 2025;104:e213365.
    >> Share

  52. ISONAKA R, Sullivan P, Goldstein DS
    Pathophysiological Significance of alpha-Synuclein in Sympathetic Nerves: In Vivo Observations.
    Neurology. 2025;104:e210215.
    >> Share

    January 2025
  53. DE BARTOLO MI, Ojha A, Leodori G, Piervincenzi C, et al
    Association of Early fMRI Connectivity Alterations With Different Cognitive Phenotypes in Patients With Newly Diagnosed Parkinson Disease.
    Neurology. 2025;104:e210192.
    >> Share

  54. KOCH MW, Kalia LV, Sarna JR, Wile D, et al
    Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease: Analysis of the PRECEPT and DATATOP Trial Datasets.
    Neurology. 2025;104:e210079.
    >> Share

  55. ZIEGLER A, Schmid M
    Efficient Study Designs for the Early-Stage Evaluation of Disease-Modifying Treatments in Parkinson Disease.
    Neurology. 2025;104:e210218.
    >> Share

    December 2024
  56. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2024;103:e210077.
    >> Share

  57. YOO HS, Kim HK, Na HK, Kang S, et al
    Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and Cognitive Deficits in Patients With Parkinson Disease.
    Neurology. 2024;103:e210105.
    >> Share

    November 2024

  58. Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e210092.
    >> Share

  59. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    >> Share

  60. AAMODT WW, Sun C, Dahodwala N, Elser H, et al
    End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases.
    Neurology. 2024;103:e209925.
    >> Share


  61. Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
    Neurology. 2024;103:e209986.
    >> Share

    October 2024
  62. KIM HK, Biessels GJ, Yu MH, Hong N, et al
    SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
    Neurology. 2024;103:e209805.
    >> Share

  63. YOU M, Grobois L, Etienne M
    Reader Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209374.
    >> Share

  64. BRENNER SR
    Reader Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209911.
    >> Share

  65. KRZYZANOWSKI B
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209334.
    >> Share

  66. LEWIS A, Galetta SL
    Editors' Note: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209851.
    >> Share

  67. KRZYZANOWSKI B
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209412.
    >> Share

    September 2024
  68. SCHULZ RS, Glatz T, Buring JE, Rist PM, et al
    Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2024;103:e209747.
    >> Share

  69. ANASTASSIADIS C, Martinez-Valbuena I, Vasilevskaya A, Thapa S, et al
    CSF alpha-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
    Neurology. 2024;103:e209818.
    >> Share

  70. GALLAGHER J, Gochanour C, Caspell-Garcia C, Dobkin RD, et al
    Long-Term Dementia Risk in Parkinson Disease.
    Neurology. 2024;103:e209699.
    >> Share

    August 2024
  71. DAYAN E
    Neuropathologic Processes Linked to Brain Network Resilience in Parkinson Disease: Local or Distributed Effects?
    Neurology. 2024;103:e209731.
    >> Share

  72. FRIGERIO I, Broeders TAA, Lin CP, Bouwman MMA, et al
    Pathologic Substrates of Structural Brain Network Resilience and Topology in Parkinson Disease Decedents.
    Neurology. 2024;103:e209678.
    >> Share

  73. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.
    Neurology. 2024;103:e209620.
    >> Share

  74. YOU J, Wang L, Wang Y, Kang J, et al
    Prediction of Future Parkinson Disease Using Plasma Proteins Combined With Clinical-Demographic Measures.
    Neurology. 2024;103:e209531.
    >> Share

  75. NISHIDA A, Shima A, Kambe D, Furukawa K, et al
    Frontoparietal-Striatal Network and Nucleus Basalis Modulation in Patients With Parkinson Disease and Gait Disturbance.
    Neurology. 2024;103:e209606.
    >> Share

  76. PARNETTI L, Gaetani L
    Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases.
    Neurology. 2024;103:e209600.
    >> Share

  77. MERINO RUIZ MC, Mortari MR
    Neurotransmitters and Networks Interplay in Cognition and Gait Disturbances in Patients With Parkinson Disease: Beyond Lesion Localization.
    Neurology. 2024;103:e209704.
    >> Share

    July 2024
  78. YOUNG CB, Cholerton B, Smith AM, Shahid-Besanti M, et al
    The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
    Neurology. 2024;103:e209609.
    >> Share

  79. OH Y, Kim JS, Lyoo CH, Park G, et al
    Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment.
    Neurology. 2024;103:e209498.
    >> Share

  80. HILKENS NA, Hammerton G, De Vries NM, Bloem BR, et al
    Guide to Decomposition of Causal Effects Into Mediation, Interaction, and Direct Effects: Case Study on Aerobic Exercise and Parkinson Disease.
    Neurology. 2024;103:e209547.
    >> Share

    June 2024
  81. KIM S, Na HK, Sun Y, Yoon YJ, et al
    Regional Burden of Enlarged Perivascular Spaces and Cognition and Neuropsychiatric Symptoms in Drug-Naive Patients With Parkinson Disease.
    Neurology. 2024;102:e209483.
    >> Share

  82. LE HERON C, Horne KL, MacAskill MR, Livingstone L, et al
    Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2024;102:e209301.
    >> Share

  83. DI LUCA DG, Perlmutter JS
    Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet.
    Neurology. 2024;102:e209558.
    >> Share

  84. HOY CW, Chiong W
    The Ethical Landscape of Prodromal Parkinson Disease: Considerations for Shared Decision-Making and Health Equity.
    Neurology. 2024;102:e209522.
    >> Share

  85. HASTINGS A, Cullinane P, Wrigley S, Revesz T, et al
    Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.
    Neurology. 2024;102:e209453.
    >> Share

  86. REES RN, Noyce AJ, Schrag AE
    Identification of Prodromal Parkinson Disease: We May Be Able to But Should We?
    Neurology. 2024;102:e209394.
    >> Share

    May 2024
  87. RUS T, Cuderman A, Georgiev D
    Parkinsonism Associated With Traumatic Hemorrhage in Substantia Nigra: Role of Presynaptic Dopaminergic Imaging.
    Neurology. 2024;102:e209384.
    >> Share

  88. DOPPLER CEJ, Seger A, Farrher E, Regio Brambilla C, et al
    Glutamate Signaling in Patients With Parkinson Disease With REM Sleep Behavior Disorder.
    Neurology. 2024;102:e209271.
    >> Share

    April 2024
  89. BROWN G, De Jesus S
    Bridging the Gap: Local Field Potentials Offer a Peek Into the Brain of a Person With Parkinson Disease.
    Neurology. 2024;102:e209283.
    >> Share

  90. ZHAO Y, Lai Y, Konijnenberg H, Huerta JM, et al
    Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort.
    Neurology. 2024;102:e209201.
    >> Share

  91. ZHANG D, Zhou L, Lu C, Feng T, et al
    Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.
    Neurology. 2024;102:e209220.
    >> Share

  92. LAPADAT A, Nielsen SS, Racette B, Krzyzanowski B, et al
    Application of Simazine, Atrazine, and Lindane Pesticides Are Associated with Incident Parkinson's Disease Risk in the Rocky Mountain Region (S2.002).
    Neurology. 2024;102.
    >> Share

  93. CAMPBELL M, Grossen S, Carr E, Eid A, et al
    Precision-mapping Functional Connectivity in Parkinson Disease: Feasibility & Reliability (P7-3.005).
    Neurology. 2024;102.
    >> Share

  94. THOMAS E, Walker H, Middlebrooks E, McCullough B, et al
    Frameless, Virtual Cone Linac-based Stereotactic Radiosurgery for Essential & Parkinsonian Tremor: A Phase I/II Prospective Clinical Trial (S35.001).
    Neurology. 2024;102.
    >> Share

    March 2024
  95. PARNETTI L, Paoletti FP
    Fluid Biomarkers for Trial Enrichment and Effect Monitoring in Disease-Modifying Treatments for Parkinson Disease.
    Neurology. 2024;102:e209194.
    >> Share

  96. HUTCHISON RM, Fraser K, Yang M, Fox T, et al
    Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
    Neurology. 2024;102:e209137.
    >> Share

    February 2024
  97. TURNER RS
    Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?
    Neurology. 2024;102:e208097.
    >> Share

  98. TOSIN MH, Goetz CG, Stebbins GT
    Patient With Parkinson Disease and Care Partner Perceptions of Key Domains Affecting Health-Related Quality of Life.
    Neurology. 2024;102:e208028.
    >> Share

  99. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    >> Share

  100. RAHAYEL S, Postuma R, Baril AA, Misic B, et al
    (99m)Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder.
    Neurology. 2024;102:e208015.
    >> Share

    January 2024
  101. KAHLON S, Barton CR, Abu Libdeh A, O'Malley JA, et al
    Emerging Subspecialties: Pediatric Movement Disorders Neurology.
    Neurology. 2024;102:e208050.
    >> Share

    December 2023
  102. ELLIOTT JE, Bryant-Ekstrand MD, Keil AT, Ligman BR, et al
    Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;101:e2545-e2559.
    >> Share

  103. ISHIKAWA K
    How Certain Are You When Making the Diagnosis of Multiple System Atrophy?
    Neurology. 2023;101:1081-1082.
    >> Share

    November 2023
  104. PURNER D, Hormozi M, Weiss D, Barbe MT, et al
    Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
    Neurology. 2023 Nov 1:10.1212/WNL.0000000000207858.
    >> Share

    October 2023
  105. KRZYZANOWSKI B, Nielsen SS, Turner JR, Racette BA, et al
    Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2023 Oct 30:10.1212/WNL.0000000000207871.
    >> Share

  106. DARWEESH SK, Burke JF, Peters S
    Air Pollution and Parkinson Disease: Increasing Our Risk Each Breath We Take?
    Neurology. 2023 Oct 30:10.1212/WNL.0000000000207972.
    >> Share

  107. ROMANOWSKA J, Bjornevik K, Cortese M, Tuominen JA, et al
    Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207899.
    >> Share

  108. BEAUCHAMP LC, Dore V, Villemagne VL, Xu S, et al
    Utilizing (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207748.
    >> Share

    August 2023
  109. RAMATCHANDIRANE B, Rebello A, Syamala DD, Ganne P, et al
    Bilateral Iris Atrophy in a Patient With Parkinsonism.
    Neurology. 2023 Aug 30:10.1212/WNL.0000000000207743.
    >> Share

  110. KOSKA V, Albrecht P
    Inner Retinal Thickness Changes in Prevalent and Incident Parkinson Disease: A Potential Biomarker With Prognostic Value?
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207780.
    >> Share

  111. WAGNER SK, Romero-Bascones D, Cortina-Borja M, Williamson DJ, et al
    Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease.
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207727.
    >> Share

  112. ALTAMIMI R, Aldhalaan H, Tous E, Nicolas-Jilwan M, et al
    Teaching NeuroImages: The Putaminal Eye, A Highly Characteristic Imaging Feature of MEGDEL Syndrome.
    Neurology. 2023 Aug 21:10.1212/WNL.0000000000207823.
    >> Share

  113. PARNETTI L, Bellomo G
    Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
    >> Share

  114. TSUKITA K, Sakamaki-Tsukita H, Kaiser S, Zhang L, et al
    High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207725.
    >> Share

  115. FRANKLIN GL
    A Letter From a Wise Man With Parkinson Disease.
    Neurology. 2023 Aug 1:10.1212/WNL.0000000000207660.
    >> Share

    July 2023
  116. CAMICIOLI RM, Colosimo C
    Neuropsychiatric Symptoms and Parkinson Disease: Are We Looking Carefully Enough?
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207722.
    >> Share

  117. LEE YG, Park M, Jeong SH, Baik K, et al
    Association of Neuropsychiatric Symptom Profiles With Cognitive Decline in Patients With Parkinson Disease and Mild Cognitive Impairment.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207623.
    >> Share

  118. BENARROCH E
    What Is the Role of the Intralaminar Thalamic Input to the Striatum and Its Potential Implications in Parkinson Disease?
    Neurology. 2023;101:118-123.
    >> Share

  119. AGRAWAL S, Leurgans SE, Nag S, Oveisgharan S, et al
    Effects of Cerebrovascular and Lewy Body Pathology on Parkinsonian Signs in Community-Dwelling Older Adults.
    Neurology. 2023 Jul 12:10.1212/WNL.0000000000207497.
    >> Share

    June 2023

  120. Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207614.
    >> Share

  121. NELSON PT, Jicha GA
    Surprising Synergy Between Cerebrovascular and Lewy Body Disease in Parkinsonism.
    Neurology. 2023 Jun 21:10.1212/WNL.0000000000207572.
    >> Share

  122. ZHANG Y, Zhang Y, Mao C, Jiang Z, et al
    Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease.
    Neurology. 2023 Jun 2:10.1212/WNL.0000000000207410.
    >> Share

    May 2023
  123. WANG L, Zhou C, Zhang W, Zhang M, et al
    Association of Cortical and Subcortical Microstructure with Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207408.
    >> Share

  124. PORTUGAL B, Artaud F, Degaey I, Roze E, et al
    Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.
    Neurology. 2023 May 17:10.1212/WNL.0000000000207424.
    >> Share

  125. CHAHINE LM, Darweesh SKL
    Physical Activity and the Risk of Parkinson Disease: Moving in the Right Direction.
    Neurology. 2023 May 17:10.1212/WNL.0000000000207527.
    >> Share

  126. IRANZO A, Mammana A, Munoz-Lopetegi A, Dellavalle S, et al
    Misfolded alpha-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;100:e1944-e1954.
    >> Share

    April 2023
  127. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
    Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
    Neurology. 2023;100:e1691-e1701.
    >> Share

  128. PARNETTI L, Bellomo G
    On the Track of alpha-Synuclein in the Body: Skin Biopsies for Diagnosing Synucleinopathies?
    Neurology. 2023;100:691-692.
    >> Share

  129. DI LUCA DG, Luo S, Liu H, Cohn M, et al
    Racial and Ethnic Differences in Health-Related Quality of Life for Individuals with Parkinson Disease Across Centers of Excellence.
    Neurology. 2023 Apr 5:10.1212/WNL.0000000000207247.
    >> Share

    February 2023
  130. REYNOLDS EL, Gallagher G, Hill CE, Banerjee M, et al
    Costs and Utilization of New-to-Market Neurologic Medications.
    Neurology. 2023;100:e884-e898.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016